Pharmacoepidemiology and Pharmacoeconomics

University of Groningen > Faculty of Science and Engineering > Faculty Board FSE > FSE Research > Groningen Research Institute of Pharmacy > Pharmacoepidemiology and Pharmacoeconomics

  1. 2017
  2. Moradi-Lakeh, M., El Bcheraoui, C., Khalil, I., Charara, R., Afshin, A., Wang, H., ... Gbd 2015 Eastern Mediterranean Region Diabetes And Ckd Collaborators (2017). Diabetes mellitus and chronic kidney disease in the Eastern Mediterranean Region: findings from the Global Burden of Disease 2015 study. International Journal of Public Health. DOI: 10.1007/s00038-017-1014-1
  3. 2016
  4. Rours, G. I. J. G., Smith-Norowitz, T. A., Ditkowsky, J., Hammerschlag, M. R., Verkooyen, R. P., de Groot, R., ... Postma, M. (2016). Cost-effectiveness analysis of Chlamydia trachomatis screening in Dutch pregnant women. Pathogens and Global Health, 110(7-8), 292-302. DOI: 10.1080/20477724.2016.1258162
  5. Mafirakureva, N., Mapako, T., Khoza, S., Emmanuel, J. C., Marowa, L., Mvere, D., ... van Hulst, M. (2016). Cost effectiveness of adding nucleic acid testing to hepatitis B, hepatitis C, and human immunodeficiency virus screening of blood donations in Zimbabwe. Transfusion, 56(12), 3101-3111. DOI: 10.1111/trf.13858
  6. Dolk, C., Eichner, M., Welte, R., Anastassopoulou, A., Van Bellinghen, L-A., Nautrup, B. P., ... Postma, M. (2016). Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model. Pharmacoeconomics, 34(12), 1299-1308. DOI: 10.1007/s40273-016-0443-7
  7. Blommestein, H. M., de Groot, S., Aarts, M. J., Vemer, P., de Vries, R., van Abeelen, A. F. M., ... Uyl-de Groota, C. A. (2016). Cost-effectiveness of obinutuzumab for chronic lymphocytic leukaemia in The Netherlands. Leukemia Research, 50, 37-45. DOI: 10.1016/j.leukres.2016.09.005
  8. van den Houten, M. M. L., Lauret, G. J., Fakhry, F., Fokkenrood, H. J. P., van Asselt, A. D. I., Hunink, M. G. M., & Teijink, J. A. W. (2016). Cost-effectiveness of supervised exercise therapy compared with endovascular revascularization for intermittent claudication. British Journal of Surgery, 103(12), 1616-1625. DOI: 10.1002/bjs.10247
  9. Stevanovic, J., de Jong, L. A., Kappelhoff, B. S., Dvortsin, E. P., Voorhaar, M., & Postma, M. J. (2016). Dabigatran for the Treatment and Secondary Prevention of Venous Thromboembolism; A Cost-Effectiveness Analysis for the Netherlands. PLoS ONE, 11(10), e0163550. [0163550]. DOI: 10.1371/journal.pone.0163550
  10. Dunlop, W. C. N., Mullins, C. D., Pirk, O., Goeree, R., Postma, M. J., Enstone, A., & Heron, L. (2016). BEACON: A Summary Framework to Overcome Potential Reimbursement Hurdles. Pharmacoeconomics, 34(10), 1051-1065. DOI: 10.1007/s40273-016-0427-7
  11. Pouwels, K. B., Bozdemir, S. E., Yegenoglu, S., Celebi, S., McIntosh, E. D., Unal, S., ... Hacimustafaoglu, M. (2016). Potential Cost-Effectiveness of RSV Vaccination of Infants and Pregnant Women in Turkey: An Illustration Based on Bursa Data. PLoS ONE, 11(9), [0163567]. DOI: 10.1371/journal.pone.0163567
Previous 1 2 3 4 5 6 7 8 ...28 Next

ID: 32629